Ducruet Andrew F, Hickman Zachary L, Zacharia Brad E, Grobelny Bartosz T, DeRosa Peter A, Landes Elissa, Lei Shuang, Khandji Joyce, Gutbrod Sarah, Connolly E Sander
Department of Neurological Surgery, Columbia University, New York, NY 10032, USA.
Neurol Res. 2010 Sep;32(7):706-10. doi: 10.1179/174313209X459129.
Patients receiving antiplatelet medications are reported to be at increased risk for hematoma enlargement and worse clinical outcomes following intracerebral hemorrhage (ICH). While platelet transfusions are frequently administered to counteract qualitative platelet defects in the setting of ICH, conclusive evidence in support of this therapeutic strategy is lacking. In fact, platelet transfusions may be associated with adverse effects, and represent a finite resource. We sought to determine the clinical efficacy of platelet transfusion and its impact on systemic complications following ICH in a cohort of patients receiving antiplatelet medications.
We retrospectively analysed the medical records of 66 patients admitted to our institution from June 2003 to July 2008 who suffered a primary ICH while receiving antiplatelet (acetylsalicylic acid and/or clopidogrel) therapy. The primary outcome was the rate of significant (>25% increase from admission) hematoma expansion in transfused (n=35) versus non-transfused (n=31) patients. Discharge modified-Rankin score (mRS) and the rates of systemic complications were also assessed.
There were no statistically significant differences in rates of hematoma expansion between cohorts, nor were there differences in demographic variables, systemic complications or discharge mRS. Subgroup analysis revealed that there was a higher rate of hematoma expansion in the clopidogrel cohort (p=0.034) than in the cohort of patients receiving aspirin alone.
This study suggests that platelet administration does not reduce the frequency of hematoma expansion in ICH patients receiving antiplatelet medications. This lack of efficacy may relate to transfusion timing, as a significant proportion of hematoma expansion occurs within 6 hours post-ictus. Additionally, the increased rates of hematoma expansion in the clopidogrel cohort may relate to its prolonged half-life. A larger, prospective study is warranted.
据报道,接受抗血小板药物治疗的患者在脑出血(ICH)后发生血肿扩大及临床预后较差的风险增加。虽然在脑出血情况下经常输注血小板以对抗血小板质量缺陷,但缺乏支持这种治疗策略的确凿证据。事实上,血小板输注可能会带来不良反应,且是一种有限的资源。我们试图确定血小板输注在一组接受抗血小板药物治疗的脑出血患者中的临床疗效及其对全身并发症的影响。
我们回顾性分析了2003年6月至2008年7月期间入住我院的66例在接受抗血小板(阿司匹林和/或氯吡格雷)治疗时发生原发性脑出血患者的病历。主要结局是接受输血(n = 35)与未输血(n = 31)患者中血肿显著扩大(较入院时增加>25%)的发生率。还评估了出院时改良Rankin量表(mRS)评分及全身并发症的发生率。
各队列之间血肿扩大发生率无统计学显著差异,在人口统计学变量、全身并发症或出院时mRS评分方面也无差异。亚组分析显示,氯吡格雷组的血肿扩大发生率(p = 0.034)高于仅接受阿司匹林治疗的患者组。
本研究表明,对于接受抗血小板药物治疗的脑出血患者,输注血小板并不能降低血肿扩大的频率。这种缺乏疗效可能与输血时机有关,因为相当一部分血肿扩大发生在发病后6小时内。此外,氯吡格雷组血肿扩大发生率增加可能与其半衰期延长有关。有必要进行一项更大规模的前瞻性研究。